Age-dependent prognostic value of KRAS mutation in metastatic colorectal cancer

Muhammet Ozer; Suleyman Yasin Goksu; Nina Niu Sanford; Chul Ahn; Muhammad Shaalan Beg; Syed Mohammad Ali Kazmi

doi:10.2217/fon-2021-0650

Age-dependent prognostic value of KRAS mutation in metastatic colorectal cancer

Muhammet Ozer, Suleyman Yasin Goksu, Nina Niu Sanford, Chul Ahn, Muhammad Shaalan Beg, Syed Mohammad Ali Kazmi

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Background: The age-dependent prognostic impact of KRAS status in metastatic colorectal cancer (mCRC) is unknown. Materials & Methods: We used the National Cancer Database to evaluate the survival by KRAS status for age-groups <50, 50-69 and ≥70, adjusting for relevant patient and tumor characteristics. Results: mCRC patients (n = 26,095; 33.5%) had KRAS status reported, and 11,338 of these patients (43.4%) had mutations in the KRAS gene. Patients with KRAS mutations had worse overall survival than wild-type KRAS patients. In age-groups <50 years (23 vs 29 months; p < 0.001) and 50-69 (21 vs 23.4 months; p < 0.001), KRAS mutations were significantly associated with worse survival, whereas in the ≥70-year age-group, there was no significant association (14 vs 14 months; p = 0.34). Conclusion: We conclude that the age of patients influences the prognostic value of KRAS mutation in metastatic colorectal cancer.

Original language	English (US)
Pages (from-to)	4883-4893
Number of pages	11
Journal	Future Oncology
Volume	17
Issue number	35
DOIs	https://doi.org/10.2217/fon-2021-0650
State	Published - Dec 2021

Keywords

KRAS
age of onset
colorectal neoplasms
database
metastasis

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2021-0650

Cite this

@article{daa30bc7386d4e41b4177475ecb6ffbf,

title = "Age-dependent prognostic value of KRAS mutation in metastatic colorectal cancer",

abstract = "Background: The age-dependent prognostic impact of KRAS status in metastatic colorectal cancer (mCRC) is unknown. Materials & Methods: We used the National Cancer Database to evaluate the survival by KRAS status for age-groups <50, 50-69 and ≥70, adjusting for relevant patient and tumor characteristics. Results: mCRC patients (n = 26,095; 33.5%) had KRAS status reported, and 11,338 of these patients (43.4%) had mutations in the KRAS gene. Patients with KRAS mutations had worse overall survival than wild-type KRAS patients. In age-groups <50 years (23 vs 29 months; p < 0.001) and 50-69 (21 vs 23.4 months; p < 0.001), KRAS mutations were significantly associated with worse survival, whereas in the ≥70-year age-group, there was no significant association (14 vs 14 months; p = 0.34). Conclusion: We conclude that the age of patients influences the prognostic value of KRAS mutation in metastatic colorectal cancer.",

keywords = "KRAS, age of onset, colorectal neoplasms, database, metastasis",

author = "Muhammet Ozer and Goksu, {Suleyman Yasin} and Sanford, {Nina Niu} and Chul Ahn and Beg, {Muhammad Shaalan} and {Ali Kazmi}, {Syed Mohammad}",

note = "Funding Information: This work was supported by a National Cancer Institute Cancer Center Support Grant to University of Texas Southwestern Medical Center (5P30CA142543-07) to M Beg. The research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award no. UL1TR001105. M Beg is Designated Dedman Family Scholar in Clinical Care. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2021 Future Medicine Ltd.",

year = "2021",

month = dec,

doi = "10.2217/fon-2021-0650",

language = "English (US)",

volume = "17",

pages = "4883--4893",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "35",

}

TY - JOUR

T1 - Age-dependent prognostic value of KRAS mutation in metastatic colorectal cancer

AU - Ozer, Muhammet

AU - Goksu, Suleyman Yasin

AU - Sanford, Nina Niu

AU - Ahn, Chul

AU - Beg, Muhammad Shaalan

AU - Ali Kazmi, Syed Mohammad

N1 - Funding Information: This work was supported by a National Cancer Institute Cancer Center Support Grant to University of Texas Southwestern Medical Center (5P30CA142543-07) to M Beg. The research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award no. UL1TR001105. M Beg is Designated Dedman Family Scholar in Clinical Care. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2021 Future Medicine Ltd.

PY - 2021/12

Y1 - 2021/12

N2 - Background: The age-dependent prognostic impact of KRAS status in metastatic colorectal cancer (mCRC) is unknown. Materials & Methods: We used the National Cancer Database to evaluate the survival by KRAS status for age-groups <50, 50-69 and ≥70, adjusting for relevant patient and tumor characteristics. Results: mCRC patients (n = 26,095; 33.5%) had KRAS status reported, and 11,338 of these patients (43.4%) had mutations in the KRAS gene. Patients with KRAS mutations had worse overall survival than wild-type KRAS patients. In age-groups <50 years (23 vs 29 months; p < 0.001) and 50-69 (21 vs 23.4 months; p < 0.001), KRAS mutations were significantly associated with worse survival, whereas in the ≥70-year age-group, there was no significant association (14 vs 14 months; p = 0.34). Conclusion: We conclude that the age of patients influences the prognostic value of KRAS mutation in metastatic colorectal cancer.

AB - Background: The age-dependent prognostic impact of KRAS status in metastatic colorectal cancer (mCRC) is unknown. Materials & Methods: We used the National Cancer Database to evaluate the survival by KRAS status for age-groups <50, 50-69 and ≥70, adjusting for relevant patient and tumor characteristics. Results: mCRC patients (n = 26,095; 33.5%) had KRAS status reported, and 11,338 of these patients (43.4%) had mutations in the KRAS gene. Patients with KRAS mutations had worse overall survival than wild-type KRAS patients. In age-groups <50 years (23 vs 29 months; p < 0.001) and 50-69 (21 vs 23.4 months; p < 0.001), KRAS mutations were significantly associated with worse survival, whereas in the ≥70-year age-group, there was no significant association (14 vs 14 months; p = 0.34). Conclusion: We conclude that the age of patients influences the prognostic value of KRAS mutation in metastatic colorectal cancer.

KW - KRAS

KW - age of onset

KW - colorectal neoplasms

KW - database

KW - metastasis

UR - http://www.scopus.com/inward/record.url?scp=85120649213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120649213&partnerID=8YFLogxK

U2 - 10.2217/fon-2021-0650

DO - 10.2217/fon-2021-0650

M3 - Article

C2 - 34758634

AN - SCOPUS:85120649213

SN - 1479-6694

VL - 17

SP - 4883

EP - 4893

JO - Future Oncology

JF - Future Oncology

IS - 35

ER -

Age-dependent prognostic value of KRAS mutation in metastatic colorectal cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this